3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
8
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
3
Melanoma
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Glioblastoma
2
Central Nervous System Neoplasms
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Adenocarcinoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Interventions
Bevacizumab
6
Paclitaxel
5
Leucovorin
5
Irinotecan
5
Fluorouracil
5
napabucasin
4
Gemcitabine
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
Ocoxin
3
Imatinib Mesylate
3
Drug Therapy
3
palbociclib
2
entinostat
2
encorafenib
2
Oxaliplatin
2
Levoleucovorin
2
Folfox protocol
2
Everolimus
2
Cisplatin
2
Cetuximab
2
5,10-methylenetetrahydrofolic acid
2
spartalizumab
1
ribociclib
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
olaparib
1
linifanib
1
irinotecan sucrosofate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Digestive System Neoplasms
×
Immunotherapy
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled